Clinical phase II trial to evaluate the safety and efficacy of treosulfan based conditioning prior to allogenic haematopoietic stem cell transplantation in patients with haematological malignancies. - ND

OSPEDALE S. RAFFAELE0 个研究点目标入组 0 人开始时间: 2006年3月30日最近更新: 2021年10月26日

试验速览

暂无简介。

•1.Patients with haematological malignancies acute myeloid leukaemia-AML, acute lymphoblast leukemia-ALL, chronic myeloid leukemia-CML, myelodysplastic syndrome-MDS, diffuse large cell lymphoma-DLCL, Hodgkin lymphoma, chronic lymphocytic leukemia-CLL, multiple myeloma-MM or other heamatological malignancies indicated for allogeneic transplantation .2.Availability of an HLA-identical sibling donor MRD or HLA-identical unrelated donor MUD HLA-identity defined by the following markers A, B, DRB1, DQB1. 3. Target graft size unmanipulated - bone marrow 2 - 10 x 106 CD34 cells/kg BW recipient or 2 x 108 nucleated cells/kg BW recipient or - peripheral blood 4 - 10 x 106 CD34 cells/kg BW recipient4. Age 18 and 70 years 65 for MUD only 5. Karnofsky Index 80 6. Adequate contraception in female patients of child-bearing potential 7. Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Secondary malignancies2. Previous allogeneic transplantation3. Severe concomitant illnesses / medical conditions e.g. impaired respiratory and/or cardiac function 4. Known and manifested malignant involvement of the CNS 5. Active infectious disease 6. HIV- positivity or active hepatitis infection7. Impaired liver function Bilirubin upper normal limit; Transaminases 3.0 x upper normal limit 8. Impaired renal function Creatinine-clearance 60 ml/min; Serum Creatinine 1.5 x upper normal limit .9. Pleural effusion or ascites 1.0 L 10. Pregnancy or lactation11. Known hypersensitivity to treosulfan and/or fludarabine12. Participation in another experimental drug trial within 4 weeks before day -613. Non-co-operative behaviour or non-compliance 14. Psychiatric diseases or conditions that might impair the ability to give informed consent

发起方

OSPEDALE S. RAFFAELE